Quince Therapeutics shares rise 21.12% intraday after management announced December investor events and analysts gave 'Moderate Buy' ratings with $8.00 target price.

miércoles, 26 de noviembre de 2025, 10:17 am ET1 min de lectura
QNCX--
Quince Therapeutics surged 21.12% intraday, driven by the company's announcement that its executive management will participate in December investor events, including the Piper Sandler Healthcare Conference, and eight analysts covering the stock with an average "Moderate Buy" rating and an $8.00 price target.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios